GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy.
M CaforioS IacovelliC QuintarelliF LocatelliValentina FolgieroPublished in: Journal of experimental & clinical cancer research : CR (2024)
Here we will provide a comprehensive collection of the actual GMP-grade CRISPR/Cas9-mediated approaches used to support cancer therapy highlighting how this technology is opening new opportunities for treating tumors.